GURU.Markets stock price, segment price, and overall market index valuation
The company's share price XBiotech Inc.
XBiotech develops therapeutic antibodies. Its stock price reflects its unique business model, which includes both developing its own drugs and selling its manufacturing technologies to other companies, creating a diversified news stream.
Share prices of companies in the market segment - Cancer cure
XBiotech has developed the True Human™ platform for the discovery and production of therapeutic antibodies derived directly from the human immune response for the treatment of various diseases. We have classified it in the "Cancer Cure" segment. The chart below shows the overall dynamics of the biotech sector developing innovative therapeutic platforms.
Broad Market Index - GURU.Markets
XBiotech is a biotech company that discovers and develops therapeutic antibodies based on natural human antibodies. As a unique player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with XBiotech's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
XBIT - Daily change in the company's share price XBiotech Inc.
XBiotech Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the clinical trials of its therapeutic antibodies, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Cancer cure
XBiotech Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the clinical trials of its therapeutic antibodies, serving as a risk assessment tool.
Daily change in the price of a broad market stock, index - GURU.Markets
XBiotech develops therapeutic antibodies derived from people with natural immunity to certain diseases. This innovative biotech company's shares are driven by research data. Its story exemplifies the medical technology sector's contribution to overall market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization XBiotech Inc.
XBiotech Inc.'s year-over-year performance tells the story of its unique True Human™ antibody discovery platform. Its market cap change over the past 12 months reflects not only the progress of its own developments but also its strategy for licensing its antibodies to major pharmaceutical companies. The deal with Johnson & Johnson is a key validation of the value of its approach.
Annual dynamics of market capitalization of the market segment - Cancer cure
XBiotech Inc. is a biotech company with a unique antibody discovery platform. After selling its key drug, the company is focusing on new developments. The chart below shows how the market views the potential of its scientific platform and its ability to create the next hit.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
XBiotech is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization XBiotech Inc.
XBiotech develops therapeutic antibodies. Its monthly performance reflects progress in its clinical programs. Key drivers, potentially causing sharp fluctuations, include news of research results and technology licensing deals with major pharmaceutical partners.
Monthly dynamics of market capitalization of the market segment - Cancer cure
XBiotech Inc. is a biopharmaceutical company that has developed its proprietary True Human technology for the discovery and production of therapeutic antibodies derived directly from humans. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how its unique scientific approach, aimed at creating natural antibodies, is progressing in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
XBiotech develops therapeutic antibodies based on the natural human immune system. It is a biotech company whose value depends on the success of clinical trials. The chart shows monthly fluctuations, which reflect not general market sentiment, but investor confidence in its unique scientific approach.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization XBiotech Inc.
XBiotech, a company developing therapeutic antibodies based on natural human antibodies, exhibits high volatility. Weekly stock performance is driven by news of clinical trials and partnerships, reflecting the potential of its unique platform.
Weekly dynamics of market capitalization of the market segment - Cancer cure
XBiotech is developing True Human™ therapeutic antibodies. This unique approach could set the company apart from its competitors. This chart will help compare its weekly performance with the biotech sector and understand the extent to which investors believe in the superiority of its scientific platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
XBiotech is a biotech company developing antibody-based therapies. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that XBIT's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
XBIT - Market capitalization of the company XBiotech Inc.
XBiotech's chart is a financial history of the search for "superantibodies" in human blood. This company's market cap reflects its belief in its unique platform for discovering natural antibodies that can fight disease. Its dynamics are a barometer of its research progress and its ability to turn these discoveries into commercial drugs.
XBIT - Share of the company's market capitalization XBiotech Inc. within the market segment - Cancer cure
XBiotech's market share in the oncology sector is based on its unique True Human™ technology, which enables the creation of antibodies derived directly from humans. Its market share reflects the potential of this approach to create safer and more effective treatments for cancer and inflammatory diseases.
Market capitalization of the market segment - Cancer cure
XBiotech develops therapeutic antibodies derived from people with natural immunity to certain diseases. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investors' faith in this unique scientific approach.
Market capitalization of all companies included in a broad market index - GURU.Markets
XBiotech has developed a platform for discovering and producing natural human antibodies to treat diseases. Its market capitalization is based on this technology. The chart below shows the economic weight of companies that harness the human immune system to create drugs.
Book value capitalization of the company, segment and market as a whole
XBIT - Book value capitalization of the company XBiotech Inc.
XBiotech's book value is derived from its unique antibody production platform and capital. The chart below shows the underlying assets for its research and development. Its stable level after the J&J asset sale reflects its current R&D-focused strategy.
XBIT - Share of the company's book capitalization XBiotech Inc. within the market segment - Cancer cure
XBiotech develops therapeutic antibodies. The company has its own manufacturing facilities, giving it control over the process. The asset share chart shows how its physical base supports both research and potential production of innovative drugs.
Market segment balance sheet capitalization - Cancer cure
XBiotech has developed a unique platform for antibody discovery. Its key assets include not only patents but also its own manufacturing and research facilities. This makes it more capital-intensive than a purely R&D startup. The graph will show whether this model is the norm for the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
XBiotech's core competencies include manufacturing facilities and a unique platform for discovering natural human antibodies for the development of targeted therapies. The company's assets lie in its ability to find "keys" to treating various diseases, from cancer to infections, in human blood.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - XBiotech Inc.
XBiotech develops antibodies to treat various diseases. Its uniqueness lies in its proprietary manufacturing technology, which enables rapid drug development. Its market capitalization reflects the potential of this platform. The chart shows how the market values its ability to translate this technological prowess into commercially successful drugs.
Market to book capitalization ratio in a market segment - Cancer cure
XBiotech develops antibodies for the treatment of various diseases. The company's uniqueness lies in its production platform. The chart shows how the market evaluates not only its drug candidates but also the production technology itself, which can be licensed to other companies.
Market to book capitalization ratio for the market as a whole
XBiotech develops therapeutic antibodies derived from people with natural immunity to certain diseases. The chart shows how the market values this unique approach to drug discovery. Its market capitalization reflects the potential of its platform for creating "natural" drugs, which is a bet on the success of clinical trials.
Debts of the company, segment and market as a whole
XBIT - Company debts XBiotech Inc.
XBiotech develops therapeutic antibodies derived from individuals with natural immunity to certain diseases. The company's leverage during clinical trials allows it to finance the costly trials and manufacturing processes necessary to validate its unique scientific platform.
Market segment debts - Cancer cure
XBiotech has developed the True Human™ platform for the discovery and production of natural human antibodies for disease treatment. This approach is unique in the pharmaceutical industry. This chart shows common financial metrics for the biotech sector, which can be used to assess how the company funds its research and potentially licenses its discoveries to larger partners.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio XBiotech Inc.
XBiotech develops therapeutic antibodies using its proprietary True Human™ technology. The company manages the entire cycle from discovery to production independently. This chart shows how XBiotech finances its capital-intensive operations. Its debt level reflects its financial strategy and the risks associated with independence from major pharmaceutical partners.
Market segment debt to market segment book capitalization - Cancer cure
XBiotech's development of antibodies to treat cancer and other diseases relies on a unique technology for extracting them from the blood of recovered individuals. This chart shows how the biotech sector funds R&D. It allows us to appreciate how XBiotech's financial model, with its nature-based approach, differs from that of companies creating synthetic antibodies.
Debt to book value of all companies in the market
XBiotech develops therapeutic antibodies derived from individuals with natural immunity to certain diseases. This unique approach requires significant investment in R&D. The chart provides context for evaluating their leverage strategy compared to traditional pharmaceutical companies.
P/E of the company, segment and market as a whole
P/E - XBiotech Inc.
This metric for XBiotech Inc., a company developing therapeutic antibodies based on natural human antibodies, reflects confidence in its unique approach. The chart shows how investors assess the potential of its scientific platform for creating new drugs for the treatment of various diseases.
P/E of the market segment - Cancer cure
This indicator represents the average valuation for the biotech sector in which XBiotech operates. It reflects the overall level of investor optimism regarding scientific breakthroughs. The chart provides a benchmark for understanding how the market values XBiotech's unique antibody platform.
P/E of the market as a whole
XBiotech has developed a platform for the discovery and production of "true human" antibodies, derived directly from individuals with natural immunity to certain diseases. This chart illustrates the biotech sentiment. It helps understand how the market views this unique technology platform and its potential for creating a new class of drugs, compared to more traditional antibody development methods.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company XBiotech Inc.
XBiotech has developed the True Human™ platform for discovering and cloning natural human antibodies for therapeutic drug development. The company's future depends on the success of its clinical programs and licensing of its technologies. This timeline reflects market expectations for its unique approach to creating drugs based on the natural human immune response.
%20P%2FE%20XBiotech%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-XBiotech-Inc.&v=1772585213817 "Chart of the company's future (projected) P/E XBiotech Inc.")
Future (projected) P/E of the market segment - Cancer cure
XBiotech has developed the True Human platform for discovering and cloning natural human antibodies for use as therapeutics. The company believes this is a safer approach. The chart reflects expectations for the biotech sector, helping to assess how the market views this unique approach to drug development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772585213832 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
XBiotech has developed a platform for the discovery and production of natural human antibodies for the treatment of various diseases, including infectious and inflammatory ones. This chart of general expectations illustrates investor sentiment toward the biotech sector. Market optimism facilitates capital raising for clinical trials and commercialization of their unique therapeutic platform.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772585213875 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit XBiotech Inc.
XBiotech develops True Human™ therapeutic antibodies derived directly from humans. This chart shows the financial results of this unique platform. Profits can be derived from both sales of the developed drugs and licensing the technology to other pharmaceutical companies.
Profit of companies in the market segment - Cancer cure
Linkage Global Inc. is likely a logistics or trading company. Its profitability depends on trade volumes and the effectiveness of supply chain management. This chart illustrates how global economic trends, trade flows, and shipping costs directly impact the financial performance of companies operating in the international logistics sector.
Overall market profit
XBiotech has developed a platform for the discovery and production of natural human antibodies for the treatment of various diseases. The company uses these antibodies to create targeted therapies. Its business model is based on scientific breakthroughs, and its success or failure in clinical trials is independent of the general economic cycles illustrated here.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company XBiotech Inc.
XBiotech has developed the True Human™ platform for discovering and producing natural human antibodies to treat diseases. The company has shifted its focus from drug development to licensing its technology. Its revenue forecast depends on the success of its partners. This chart shows analyst expectations for the value of its platform and future royalties.
%20profit%20of%20the%20company%20XBiotech%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-XBiotech-Inc.&v=1772585214024 "Graph of future (projected) profit of the company XBiotech Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
XBiotech has developed the True Human™ platform for identifying and cloning natural antibodies from the blood of people who have successfully overcome disease. These antibodies are then used to create drugs. This graph shows profitability projections for the oncology sector. It reflects the potential of XBiotech's innovative approach, which harnesses the body's own immune wisdom.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772585214048 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
XBiotech Inc. develops therapeutic antibodies derived from human studies. The company focuses on treating various diseases, including cancer. Its prospects depend on scientific breakthroughs. This earnings forecast chart is important for assessing the overall investment climate and the willingness of major pharmaceutical companies to partner or acquire in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772585214072 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - XBiotech Inc.
XBiotech has developed a platform for the discovery and production of natural human antibodies for the treatment of various diseases. Its unique approach utilizes antibodies isolated from naturally immune individuals. The chart shows the market sentiment for this innovative, yet commercially viable, technology.
P/S market segment - Cancer cure
XBiotech Inc. is a biopharmaceutical company that has developed the True Human™ platform for discovering and producing natural human antibodies to treat various diseases, including infectious and inflammatory ones. This chart shows the average valuation in the sector, allowing one to assess how the market values XBiotech's unique scientific platform.
P/S of the market as a whole
XBiotech has developed its own True Human™ technology for identifying and cloning natural human antibodies to create therapeutic drugs. The company focuses on anti-inflammatory therapies. This chart, showing average valuations, helps understand the premium the market places on the revenue of a biotech company with a unique scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company XBiotech Inc.
XBiotech develops therapeutic antibodies derived from individuals with natural immunity to certain diseases. This chart shows how investors assess the future potential of its scientific platform. This assessment is based on expectations for the successful application of this approach to the development of new drugs for cancer and infectious diseases.
%20P%2FS%20XBiotech%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-XBiotech-Inc.&v=1772585214108 "The graph of the company's future (projected) P/S XBiotech Inc.")
Future (projected) P/S of the market segment - Cancer cure
XBiotech Inc. has developed the True Human™ platform for the discovery and production of therapeutic antibodies derived directly from people with natural immunity to certain diseases. The chart shows how the market estimates XBiotech's future sales, reflecting confidence in the potential of its unique approach to creating natural and safe medicines.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772585214113 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Investor optimism about future revenues depends on new approaches to drug discovery. XBiotech, with its True Human™ technology, detects antibodies for disease treatment directly in the blood of people who have successfully overcome their illnesses. Their unique approach to drug development reflects the belief that the answers to many medical challenges lie within the human body itself.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772585214120 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales XBiotech Inc.
XBiotech has developed a unique platform for discovering and cloning natural human antibodies for use as therapeutics. The company's revenue is generated not from regular sales, but rather from large licensing fees for its technologies and drug candidates to major pharmaceutical companies.
Sales of companies in the market segment - Cancer cure
XBiotech Inc. has developed a unique technology for rapidly identifying and cloning natural human antibodies to create targeted therapies. This chart shows total revenue in the targeted oncology sector. It illustrates the potential of harnessing the body's immune system to fight disease, which is the foundation of XBiotech's innovative platform.
Overall market sales
XBiotech develops therapeutic antibodies derived from individuals with natural immunity to certain diseases. This unique approach aims to create safer and more effective drugs. The company's success depends on the results of clinical trials. This overall economic climate impacts the investment climate for innovative biotech platforms.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company XBiotech Inc.
XBiotech has developed the True Human™ platform for discovering and cloning natural human antibodies for use as therapeutics. The company is focused on treating inflammatory diseases. The chart shows analyst revenue forecasts, which are contingent on the successful commercialization of this innovative platform.
%20sales%20of%20the%20company%20XBiotech%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-XBiotech-Inc.&v=1772585214251 "Schedule of future (projected) sales of the company XBiotech Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
XBiotech has developed the True Human™ platform for the discovery and production of natural human antibodies for the treatment of various diseases, including infectious and inflammatory ones. The company believes in the power of natural immunity. This chart shows projected revenues for the entire oncology sector, providing an overview of overall expectations for the antibody-based therapeutics market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772585214284 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
XBiotech has developed a platform for the discovery and production of natural human antibodies for the treatment of various diseases. The company's business model is focused on licensing its technologies. This overall economic activity affects the R&D budgets of large pharmaceutical companies, which are potential partners and licensees for XBiotech.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772585214322 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality XBiotech Inc.
XBiotech is developing True Human™ therapeutic antibodies. This metric reflects the financial performance of its scientific platform. It shows how the company balances the costs of clinical trials of its candidate drugs with potential revenue from partnerships or future sales, striving to create a commercially successful product.
Market segment marginality - Cancer cure
XBiotech Inc. develops therapeutic antibodies based on natural antibodies isolated from humans. Profitability depends on the success of this unique True Human™ platform. This chart shows the company's operational structure and R&D investment efficiency compared to other biotech companies developing oncology drugs.
Market marginality as a whole
XBiotech develops therapeutic antibodies derived from individuals with natural immunity to certain diseases. Their "True Human" approach could lead to safer and more effective drugs. The company's success depends on clinical data. This overall profitability schedule does not affect their innovative research activities.
Employees in the company, segment and market as a whole
Number of employees in the company XBiotech Inc.
XBiotech develops therapeutic antibodies based on natural human antibodies. The company has its own manufacturing facility. This chart shows the size of its research and production team. The dynamics here reflect not only clinical trial activity but also the utilization of its unique manufacturing facilities.
Share of the company's employees XBiotech Inc. within the market segment - Cancer cure
XBiotech has developed the True Human™ platform for discovering antibodies derived from the natural human immune response. This graph shows the concentration of unique immunologists and biologists. This proportion reflects its innovative approach to creating drugs that are exact replicas of natural antibodies.
Number of employees in the market segment - Cancer cure
XBiotech Inc. is a biopharmaceutical company that has developed technology for discovering and cloning natural human antibodies to treat diseases. This chart shows overall employment in the cancer treatment sector. It illustrates the company's unique approach, which uses the human immune response as a source for developing new therapeutics.
Number of employees in the market as a whole
XBiotech Inc. has developed the True Human™ platform for discovering and cloning natural human antibodies to create targeted therapies. The company's approach is based on leveraging natural immunity. This work schedule also includes innovative biotech companies where teams of scientists are working to create next-generation drugs, changing the treatment paradigm.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company XBiotech Inc. (XBIT)
XBiotech Inc. develops therapeutic antibodies derived from individuals with natural immunity to certain diseases. This chart demonstrates the high market valuation of this unique scientific platform. As with most biotech companies, the market capitalization per employee is very high, as investors see value in the potential of the developments.
%20of%20the%20company%20XBiotech%20Inc.%20(XBIT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-XBiotech-Inc.-XBIT&v=1772585214506 "Chart of market capitalization per employee (in thousands of dollars) of the company XBiotech Inc. (XBIT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
XBiotech has developed its own platform for the discovery and production of True Human™ therapeutic antibodies. They are a biotech company with a unique approach. This metric reflects the market's appreciation for their proprietary technology. Their high market capitalization per employee demonstrates that their platform can effectively develop new drugs with a small scientific team.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772585214569 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
XBiotech Inc. develops therapeutic antibodies based on the natural human immune response. The company has a unique technological platform. The high employee valuation reflects the value of this approach and the potential for creating new drugs for the treatment of various diseases, from infectious diseases to cancer.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772585214648 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company XBiotech Inc. (XBIT)
XBiotech (XBIT) is a biotech company with a unique platform for discovering "true human" antibodies from the blood of recovered individuals. Their model is R&D and licensing. This chart shows the net profit (or loss) generated by each scientist working on these natural antibodies.
%20Chart%20XBiotech%20Inc.%20(XBIT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-XBiotech-Inc.-XBIT&v=1772585214784 "Company Profit Per Employee (in thousands of dollars) Chart XBiotech Inc. (XBIT)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
XBiotech has developed a platform for creating natural human antibodies. This track record is a benchmark for biotechnology. While XBIT focuses on R&D, their business model also includes licensing. Their effectiveness stems from the ability of a small scientific team to generate valuable intellectual property that can generate significant upfront and licensing fees.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772585214833 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
XBiotech (XBIT) develops "True Human" therapeutic antibodies (derived directly from human sources). They also provide development and manufacturing services to others. This reflects their hybrid model: losses from in-house R&D can be offset by profits from contract manufacturing.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772585214848 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee XBiotech Inc. (XBIT)
This chart for XBiotech, a company developing therapeutic antibodies based on the natural human immune response, shows the commercialization of its scientific platform. Growth in revenue per employee will depend on the success of its drugs and partnerships with major pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-XBiotech-Inc.-XBIT&v=1772585214921 "Sales chart per company employee XBiotech Inc. (XBIT)")
Sales per employee in the market segment - Cancer cure
XBiotech is a biopharmaceutical company using its proprietary antibody discovery and development platform (True Human™) to treat various diseases. This metric reflects the average revenue per employee in the segment. It helps assess how productive their R&D platform is in creating and monetizing new drugs compared to other biotech companies.
Sales per employee for the market as a whole
XBiotech (XBIT) is a biopharmaceutical company developing therapies based on "true human" antibodies. This indicator is an indicator of the future for them. Zero values currently reflect the R&D stage. A rising graph will indicate a commercial breakthrough and the success of their unique platform, or the receipt of large partnership payments for their developments.
Short shares by company, segment and market as a whole
Shares shorted by company XBiotech Inc. (XBIT)
XBiotech is developing therapeutic antibodies using its "True Human" platform. The company sold its core asset, and its value now depends on future developments and royalties. This chart reflects investor skepticism about the value of its remaining platform and its ability to create a successful new drug from scratch.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-XBiotech-Inc.-XBIT&v=1772585215050 "Short Shares Chart for the Company XBiotech Inc. (XBIT)")
Shares shorted by market segment - Cancer cure
XBiotech (XBIT) is a biopharmaceutical company with a platform for discovering and developing "truly human" antibodies derived from naturally immune individuals. This chart shows the overall short position in the biotech sector. It reflects market skepticism regarding the scalability of their platform or progress in clinical development.
Shares shorted by the overall market
XBiotech is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, unprofitable biotechs like XBIT in order to move into safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator XBiotech Inc. (XBIT)
This oscillator for XBiotech shows the reaction to its unique business model. The company discovers antibodies (True Human™ technology) and licenses them to large pharma companies rather than bringing them to market itself. "Overbought" (above 70) occurs on news of a major licensing deal. A prolonged lack of deals or failures in early studies leads to "oversold" conditions.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-XBiotech-Inc.-XBIT&v=1772585215184 "RSI 14 indicator chart for the company's stock XBiotech Inc. (XBIT)")
RSI 14 Market Segment - Cancer cure
XBiotech (XBIT) is a biotech company that specializes in *antibody* hunting. Their specialty is *True Human™* antibodies, *copied* directly from the *blood* of recovered people. The "Cancer Cure" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is XBIT's growth due to their R&D, or is *the entire* biotech sector overheated?
RSI 14 for the overall market
XBiotech (XBIT) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XBIT (XBiotech Inc.)
XBiotech is a company that developed the "True Human" platform for rapidly discovering and cloning natural human antibodies to treat diseases (e.g., infections). This chart shows the average analyst price target, reflecting their view on the platform's value and potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XBIT-XBiotech-Inc.&v=1772585215474 "A chart showing analyst consensus forecasts for the expected stock price. XBIT (XBiotech Inc.)")
The difference between the consensus estimate and the actual stock price XBIT (XBiotech Inc.)
XBIT - XBiotech is a biotech company with a unique True Human™ platform. They isolate natural antibodies from people who have successfully overcome a disease and develop them into drugs. This chart clearly demonstrates the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in this R&D model.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XBIT-XBiotech-Inc.&v=1772585215558 "A chart showing the difference between the consensus forecast and the actual stock price. XBIT (XBiotech Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
XBiotech (XBIT) is a biotech company developing patient-derived "true human" antibodies (True Human™) to treat various diseases. This chart shows overall expectations for the cancer treatment sector, reflecting the confidence of experts in this R&D platform.
Analysts' consensus forecast for the overall market share price
XBiotech (XBIT) is a biotech company that (following the sale of its flagship drug) has focused on developing "true human" antibodies to treat various diseases. This chart shows the overall risk appetite. For XBiotech, a company searching for the next big thing, overall market optimism is important for funding their innovative, yet risky, platform.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index XBiotech Inc.
XBiotech (XBIT) is a platform company. Their signature feature is True Human antibodies. They don't humanize mice, but rather find rare, powerful antibodies directly from people who have naturally overcome their disease. This graph represents their R&D bet. It measures their (slow) progress in finding these super-antibodies and their ability to turn them into drugs.
AKIMA Market Segment Index - Cancer cure
XBiotech is a company using its True Human platform to discover and develop natural human antibodies to treat diseases (including cancer). This chart shows the average index for the oncology sector. It allows investors to assess how XBiotech's scientific approach compares to the industry average.
The AKIM Index for the overall market
XBiotech is a biotech company developing "true human" antibodies to treat inflammatory diseases and cancer. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, with its unique drug discovery technology, compares to overall economic trends.
